
Oli da		
Slide 1		
	Drug Metabolism	
	Nick Holford	
	Dept Pharmacology & Clinical Pharmacology University of Auckland	
Slide		
2	Objectives	
	Understand why drug biotransformation takes place	
	<ul> <li>Be able to distinguish Phase 1 (metabolism) and Phase 2 (conjugation) biotransformation</li> </ul>	
	<ul> <li>Appreciate the role of enzyme induction and inhibition for drug biotransformation</li> </ul>	
	<ul> <li>Learn the major CYP enzymes and know at least one clinically relevant substrate for each one</li> </ul>	
	SMHG Hollott. 2011, all rights reserved.	
Slide 3	Why is Understanding	
	Biotransformation Important?	
	Major route of drug elimination	
	> Often activates/inactivates drugs	
	> May produce toxic products	
	> Source of between patient variability	
	> Explains many drug-drug interactions	
	CRMG Halford, 2021, all rights reserved.	

Clido		1
Slide 4	Biotransformations  • Two main phases	
	PHASE 1 PHASE 2 R-O-R' $(RH)$ INT $(ROH)$ PHASE 2 - CONJUGATION (SUGARS, SO <sub>4</sub> , Acetyl)	
	R-O-R' — USUALLY EXCRETED IN URINE	
Slide 5	Major Enzyme Systems	http://en.wikipedia.org/wiki/Cytoch rome_P450
	<ul><li>Phase 1</li><li>» Cytochrome P450 (CYP)</li></ul>	
	<ul> <li>Phase 2</li> <li>Transferases</li> <li>Glucuronyl-</li> <li>Sulphate-</li> <li>Acetate-</li> </ul>	
	SNHG Hallord, 2021, all rights reserved.	
Slide 6	Cytochrome P450  Synonyms  CYP  Mixed function oxidase (MFO)  Microsomal P450  Actions  Over 70% of drugs are metabolized by CYPs  Location  Gut wall  Liver	



Slide		1	
10			
	CYP1A2		
	011 17.12		
	Marker Drug theophylline		
	➤ Clinically Relevant Drugs		
	» bronchodilator (theophylline)		
	" bronchodilator (theophylline)		
	D 1.1		
	> Drug Interaction		
	» tobacco, green veges, BBQ (inducer)		
	» cimetidine (inhibitor)		
	> Ethnicity		
	» ?		
Clists	GNHO Hollord, 2001, all rights reserved.	<u> </u>	
Slide 11			
	CVD2E1		
	CYP2E1		
	➤ Marker Drug <b>ethanol</b>		
	/ Walker Brug Ctranor		
	011 11 5 1 1 5		
	Clinically Relevant Drugs		
	» analgesic paracetamol (-> NAPQI)		
	Drug Interaction		
	» ethanol (inducer)		
	> Ethnicity		
	» ?		
Slide	GNHG Holbret, 2021, all rights reserved.	<u> </u>	
12			"CYP2C9 variants with reduced
	CYP2C9		metabolizing ability were less
	G1F2G9		frequent in Japanese compared to the other two populations. "
	Marker Drug s-warfarin		Takahashi H, Wilkinson GR,
			Nutescu EA, Morita T, Ritchie
	<ul> <li>Clinically Relevant Drugs</li> </ul>		MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I,
	» anticoagulant (warfarin)		Otsubo K, Kashima T, Kimura S,
			Kijima S, Echizen H. Different
	> Adverse Event Risk		contributions of polymorphisms in VKORC1 and CYP2C9 to intra-
	» Lower dose and increased bleeding risk		and inter-population differences in
	> Ethnicity		maintenance dose of warfarin in
	» Caucasian 25%		Japanese, Caucasians and African-Americans.
	» Asian 1%		Pharmacogenet Genomics 2006;
	(% with variant alleles and lower CL)		16: 101-10.
			Japanese Caucasian
	CNHG Hotherd, 2021, all rights reserved.		CYP2C9
			*2 C430T 0.000 0.133 *3 A1075C 0.035 0.056
			Total 3.5% 18.9%

# Slide 13 Slide 14

# CYP2C19

- Marker Drug s-mephenytoin
- > Clinically Relevant Drugs
  - » acid-pump inhibitor (omeprazole)
- > Therapeutic Benefit
  - » Cure of GORD 86% in poor metabolizers, 46% in homozygous extensive metabolizers of lansoprazole
- > Drug Interaction
  - » Decreased effectiveness of clopidogrel (a prodrug),an anti-platelet agent, when combined with omeprazole (CYP2C19 inhibitor)
- > Ethnicity (% with low clearance)

» Caucasian 4%» Asian 20%

NHG Holford, 2021, all rights reserved

GORD=Gastro Oesophageal Reflux Disease

### [11/17/2009]

FDA is alerting the public to new safety information concerning an interaction between clopidogrel (Plavix), an anti-clotting medication, and omeprazole (Prilosec/Prilosec OTC), a proton pump inhibitor (PPI) used to reduce stomach acid. New data show that when clopidogrel and omeprazole are taken together, the effectiveness of clopidogrel is reduced.

Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of drugs that inhibit the activity of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition. Avoid concomitant use of drugs that inhibit CYP2C19, including omeprazole (Prilosec), esomeprazole, cimetidine, fluconazole, ketoconazole, voriconazole, etravirine, felbamate, fluoxetine, fluvoxamine, and ticlopidine

# CYP2D6

- > Marker Drug
- debrisoquine
- > Clinically Relevant Drugs
  - » tricyclic-antidepressants (amitriptyline)
  - » beta-blockers (metoprolol)
  - » prodrug analgesics (tramadol, codeine)
- > Drug Interaction
  - » fluoxetine, quinidine (inhibitor)
- > Ethnicity (% with low clearance)
  - » Caucasian 7%
  - » Asian 1%

3 Holford, 2021, all rights reserved.

Slide

15

## CYP3A4

> Marker Drug

simvastatin

- > Clinically Relevant Drugs
  - » HMG-CoA reductase inhibitor (simvastatin)
  - » protease inhibitor (anti-HIV) (lopinavir)
  - » immunosuppressant (cyclosporine)
- Drug Interaction
  - » ketoconazole, grapefruit juice (inhibitor)
  - » lopinavir with ritonavir for improved effect
  - » St John's Wort (inducer)
- > Ethnicity
- » ?
- No recognized polymorphism



30% of medicines are metabolized to with CYP3A4/5 as the major pathway Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics. 2013;138(1):103-41.

IHG Holford, 2021, all rights reserve

Slide 16			
16	CYP Activity		
	<ul> <li>Induction         <ul> <li>Increased activity</li> <li>Many substances can induce</li></ul></li></ul>		
Slide	GRHCI Hollord, 2001, all rights reserved.	<u> </u> 	Target Concentration Intervention
17	Clinical Applications  > Drug Interaction Awareness		web based dosing tool https://www.nextdose.org/
	➤ Dose Individualization  ➤ Needs  - Phenotype  □ Target Concentration Intervention  or  - Genotype □ Not widely available (yet)		
	CRH4G Hollord, 2021, all rights reserved.		